New fusion protein, useful for treating leukemia and solid tumors, comprises specific antigen-binding, microtubulin-binding and immune response-inducing regions, also related nucleic acid

摘要

Fusion protein (FP) that contains specific antigen-binding regions (AbR); microtubulin-binding regions (MbR) and immune response-inducing regions (IRIR) is new. Fusion protein (FP) that contains specific antigen-binding regions (AbR); microtubulin-binding regions (MbR) and immune response-inducing regions (IRIR) is new. Preferred AbR are EGF, FGF, CSF, MGF, IL-15 or -2, or other ligands or their regions; MbR are preferably gephyrin, tau, MAP, MID-1, MBP, put MBP, PMBP, FLJ31424fis, or their regions; and IRIR are preferably the Fc part of immunoglobulin G (IgG), B7.1 or B7.2, or their regions. Independent claims are also included for: (1) fusion protein (FP1) that contains antibody-binding regions, preferably staphylococcal protein A (SPA); extracellular regions of the Fc receptor CD64, or their regions, and MbR as above; and (2) nucleic acid and amino acid sequences; DNA (including vectors), and expression systems for FP and FP1. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Binding to microtubuli or cytoskeleton in tumor cells, so interfering with cell division and inducing cell death; also stimulation of an immune response.